Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Iron4u Aps
Novartis AG
Panion & Bf Biotech Inc
Pharmacosmos AS
Pieris Pharmaceuticals Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Vifor Pharma Ltd
Iron Deficiency Anemia - Drug Profiles
AKB-5343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ferric bepectate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iron isomaltoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru
Jan 24, 2019: Shield Therapeutics: Business and trading update
Dec 13, 2018: Shield Therapeutics announces the US new drug application PDUFA date for Feraccru
Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations
Dec 06, 2018: Clinical trial sheds new light on potential risk associated with intravenous iron treatment
Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by Norgine
Dec 04, 2018: New study demonstrates significant difference between Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation
Dec 03, 2018: Shield Therapeutics announces the new drug application for Feraccru has been accepted for filing and review by the FDA
Oct 12, 2018: Rockwell Medical provides update on IV Triferic
Oct 01, 2018: Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru for the treatment of iron deficiency with the US Food and Drug Administration (FDA)
Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose
Sep 06, 2018: Monoferric receives marketing approval from Health Cada
Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)
Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency
May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 Intertiol Congress on Peritoneal Dialysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Iron Deficiency Anemia, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Iron Deficiency Anemia, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, H1 2019
Iron Deficiency Anemia - Pipeline by Iron4u Aps, H1 2019
Iron Deficiency Anemia - Pipeline by Novartis AG, H1 2019
Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H1 2019
Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, H1 2019
Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2019
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H1 2019
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H1 2019
Iron Deficiency Anemia - Pipeline by Vifor Pharma Ltd, H1 2019
Iron Deficiency Anemia - Dormant Projects, H1 2019